Skip to content

Ketamine research published in 2024

Page 3 of 26: studies 41 to 60 of 518, newest first. Back to the ketamine overview

Studies

Ketamine-induced cystitis: A case report and literature review.

Radiology case reports December 1, 2024 Juan Felipe Betancur, Melina González Diaz Granados, Nancy Toro et al. 3 citations

Ketamine, a dissociative anesthetic drug, has gained popularity as a recreational substance, particularly among young adults. However, chronic ketamine abuse can lead to various complications including ketamine-induced cystitis. We present the case of a 46-year-old Caucasian male with a history of HIV infection and daily recreational ketamine use for 7 months, who was admitted to the emergency...

DOI: 10.1016/j.radcr.2024.08.053 (opens in new tab) Full text (opens in new tab) Bladder thickening Hematuria Recreational drug use Ureteropyeloscopy +5

Low-dose ketamine for acute pain: A narrative review.

The American Journal of Emergency Medicine December 1, 2024 Robert G Fuller, Evan M Kikla, Andrew P W Fawcett et al. 12 citations

Acute pain management is a critical component of prehospital and emergency medical care. Opioids are effective; however, the risks and side-effects of opioids have led providers to use low-dose ketamine (LDK) for safe and effective treatment of acute pain. We conducted a scoping narrative review to explore the efficacy of LDK for the treatment of acute pain in the prehospital setting and...

(2R,6R)-hydroxynorketamine alleviates PTSD-like endophenotypes by regulating the PI3K/AKT signaling pathway in rats.

Pharmacology, Biochemistry, and Behavior December 1, 2024 Lifen Liu, Rui Li, Lanxia Wu et al. 3 citations

Patients diagnosed with post-traumatic stress disorder (PTSD) mainly exhibit enduring adverse emotions, heightening susceptibility to suicidal thoughts and behaviors. Notably, metabolites of ketamine, particularly (2R,6R)-hydroxyketamine (HNK), have demonstrated favorable antidepressant properties. However, the precise mechanism through which HNK exerts its therapeutic effects on negative...

Ketamine modulates the exploratory dynamics and homebase-related behaviors of adult zebrafish.

Pharmacology, Biochemistry, and Behavior December 1, 2024 Camilla W Pretzel, João V Borba, Cássio M Resmim et al. 5 citations

Anxiety can be a protective emotion when animals face aversive conditions, but is commonly associated with various neuropsychiatric disorders when pathologically exacerbated. Drug repurposing has emerged as a valuable strategy based on utilizing the existing pharmaceuticals for new therapeutic purposes. Ketamine, traditionally used as an anesthetic, acts as a non-competitive antagonist of the...

DOI: 10.1016/j.pbb.2024.173892 (opens in new tab) Full text (opens in new tab) Nmda receptor Open field test Spatio-temporal exploration Stereotyped behavior +6

Effect of intravenous esketamine in emergency cesarean deliveries: a retrospective analysis of maternal and neonatal outcomes.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians December 1, 2024 Xiao-Mei Huang, Hong-Xia Qiu 3 citations

This study investigates the effects of administering intravenous esketamine at a dose of 0.25 mg/kg to pregnant patients receiving epidural anesthesia for emergency cesarean section on both maternal and neonatal outcomes. Medical records of pregnant patients transitioning from labor analgesia to epidural anesthesia for emergency cesarean sections between January 2020 and December 2022 were...

Molecular signature underlying (R)-ketamine rapid antidepressant response on anhedonic-like behavior induced by sustained exposure to stress.

Pharmacology, Biochemistry, and Behavior December 1, 2024 Ellen Scotton, Paola Rampelotto Ziani, Renata Luiza Boff Wilges et al. 1 citation

Anhedonia induced by sustained stress exposure is a hallmark symptom of major depressive disorder (MDD) and in rodents, it can be accessed through the sucrose preference test (SPT). (R)-ketamine is a fast-acting antidepressant with less detrimental side effects and abuse liability compared to racemic ketamine. The present study combined high-throughput proteomics and network analysis to...

DOI: 10.1016/j.pbb.2024.173882 (opens in new tab) Full text (opens in new tab) Major depressive disorder R-ketamine treatment response Anhedonic-like behavior Molecular targets +6

Pharmacotherapeutic strategies for the treatment of anorexia nervosa - novel targets to break a vicious cycle.

Expert Opinion on Pharmacotherapy December 1, 2024 Millie C Kirchberg, Claire Pinson, Guido K W Frank 9 citations

Anorexia nervosa (AN) has one of the highest mortality rates of all mental illnesses. No approved pharmacological treatments exist for AN, but novel neurobiological targets show promise. Studies show that in individuals with AN, there are alterations in brain neurotransmitter signaling, alongside associated mental rigidity and comorbid anxiety and depression. Available and new therapies could...

Intravenous ketamine infusions in patients with depression and Epilepsy: Case series.

Journal of Clinical Neuroscience December 1, 2024 Mariusz Stanisław Wiglusz, Zuzanna Chmielewska, Wiesław Jerzy Cubała 1 citation

Mood disorders affect approximately one-third of individuals with epilepsy, posing an increased risk of suicide. There is an unquestionable need for more effective antidepressant treatment in this group of patients. This study explores the safety and tolerability of low-dose intravenous ketamine in six patients with comorbid depression and epilepsy. This report is limited to the post-hoc...

DOI: 10.1016/j.jocn.2024.110908 (opens in new tab) Full text (opens in new tab) Case report Intravenous #depression-treatment depression therapy Mood disorder treatment +6

Intranasal esketamine for patients with major depressive disorder: A systematic review and meta-analysis.

Journal of Psychiatric Research December 1, 2024 Soroush Oraee, Mohammadreza Alinejadfard, Hossein Golsorkh et al. 13 citations

A large number of people worldwide grapple with Major Depressive Disorder (MDD), and a significant portion of them confront resistance to conventional antidepressant treatments. Esketamine, an innovative intervention, has garnered attention due to its rapid-acting antidepressant effects. This meta-analysis aimed to evaluate the efficacy and safety of esketamine in individuals with MDD and...

Splenic γδ T cells mediate antidepressant and prophylactic actions of arketamine in lipopolysaccharide-induced depression in mice.

Pharmacology, Biochemistry, and Behavior December 1, 2024 Guilin Liu, Li Ma, Akemi Sakamoto et al. 4 citations

Arketamine, the (R)-enantiomer of ketamine, exhibits both therapeutic and sustained prophylactic effects in an inflammation-driven model of depression, although the precise mechanisms remain elusive. Given the involvement of γδ T cells in inflammatory processes, this study explored their role in the effects of arketamine. To assess therapeutic outcomes, mice received lipopolysaccharide (LPS:1.0...

DOI: 10.1016/j.pbb.2024.173906 (opens in new tab) Full text (opens in new tab) Arketamine Prophylactic Spleen Antidepressants antidepressant medication +8

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression.

The International Journal of Neuropsychopharmacology December 1, 2024 Craig Chepke, Richard C. Shelton, Gerard Sanacora et al. 7 citations

Esketamine nasal spray (ESK) is approved, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression in adults and for the treatment of depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. No adverse events (AEs) of respiratory depression were reported in ESK phase 3 clinical trials; however, postmarketing...

DOI: 10.1093/ijnp/pyae058 (opens in new tab) Full text (opens in new tab) Esketamine nasal spray Respiratory depression Depression treatment Esketamine therapy +3

Esketamine Provides Neuroprotection After Intracerebral Hemorrhage in Mice via the NTF3/PI3K/AKT Pathway.

CNS Neuroscience & Therapeutics December 1, 2024 Xiaoyu Niu, Yuanyuan Zheng, Wang Wang et al. 7 citations

Esketamine (ESK), a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors, modulates neurotransmitter signaling in the central nervous system. However, the specific mechanisms and therapeutic potential of ESK for intracerebral hemorrhage (ICH) remain unclear. This study aimed to investigate whether ESK promotes nerve repair and improves neurological outcomes in an experimental...

DOI: 10.1111/cns.70145 (opens in new tab) Full text (opens in new tab) Esketamine Ntf3 Pi3k/akt signaling pathway Intracerebral hemorrhage +3

Safety and efficacy of ketamine use in patients with vaso-occlusive crisis: A systematic review and meta-analysis.

EJHaem December 1, 2024 Ernesto Calderon Martinez, Stephin Zachariah Saji, Thomas Campos Carmona et al. 2 citations

Sickle cell disease (SCD) is characterized by acute episodes called vaso-occlusive crises (VOC). VOC is marked by severe pain due to blocked blood vessels by sickled cells. Ketamine has been reported to be effective and safe in managing VOC in SCD patients. This review aims to determine ketamine's safety and efficacy through analysis of clinical trials and observational studies. Adhering to...

DOI: 10.1002/jha2.1050 (opens in new tab) Full text (opens in new tab) Opioids Pain management Vaso‐occlusive crisis voc Ketamine therapy +3

Navigating Treatment-Resistant Major Depressive Disorder With Suicidal Ideation: Exploring the Efficacy of Spravato (Esketamine) in an 86-Year-Old Male.

Cureus December 1, 2024 Aarman P Jivraj, Katherine A Heimer, Christopher J Wukovits et al. 1 citation

This case study examines the novel application of Spravato (intranasal esketamine) to address treatment-resistant Major Depressive Disorder (MDD) in an 86-year-old patient. Notably, this represents one of the oldest documented individuals to be administered intranasal esketamine for a diagnosis of Treatment-Resistant Depression (TRD) alongside suicidal ideation. This case study contributes to...

General Anesthesia Occludes Ketamine's Antidepressant Response in a Rodent Model of Chronic Stress.

Psychedelic Medicine December 1, 2024 Daniel Markman, Andrzej Z Wasilczuk, Joseph Michael Cichon 2 citations

Psychedelic-induced experiences are thought to play an important role in the therapeutic actions of rapid-acting antidepressants. General anesthesia is one scenario in which patients can be rendered unconscious and masked to the psychedelic treatment, providing a simple yet effective method to examine drug-induced changes in the brain devoid of experiences. Chronically stressed adult C57/BL6...

DOI: 10.1089/psymed.2024.0007 (opens in new tab) Full text (opens in new tab) Antidepressant response Chronic stress Dissociation General anesthesia +6

The role of ketamine and its enantiomer in managing depression and pain in cancer patients: A narrative review.

Journal of Anesthesia and Translational Medicine December 1, 2024 Michael S Bodnar, Sierra Barber, Heather S L Jim et al. 3 citations

Depression and pain are common comorbidities in cancer patients, and ketamine, a dissociative anesthetic, has shown potential in managing both. This review summarizes current literature on ketamine and its enantiomer, esketamine, in managing depression and pain in the oncologic population. Studies indicate that sub-anesthetic doses of intravenous ketamine and esketamine can alleviate...

DOI: 10.1016/j.jatmed.2024.10.005 (opens in new tab) Full text (opens in new tab) Anesthesia Pain management Ketamine therapy Cancer treatment +2

Learning how to make use of dissociative therapies.

International Review of Psychiatry December 1, 2024 David S. Mathai 3 citations

Dissociative therapies are being increasingly explored for their psychiatric applications, although questions remain about how they work and how best to use them. In exploring these questions, this review highlights six key areas of clinical relevance: (1) The possible contributions of functional unblinding when interpreting efficacy data; (2) The degree to which the therapeutic effects of...

Treatment-resistant depression: Established and emerging therapies.

The Nurse Practitioner December 1, 2024 Leesa A McBroom, Melissa Timmons 3 citations

In 2023, the percentage of people in the US who experienced depression in their lifetime was at an all-time high of 29%. Depression causes considerable distress and functional impairment affecting quality of life, employment, and interpersonal relationships. Many patients fail to respond to treatment with antidepressants and psychological-behavioral therapy, resulting in a condition known as...

DOI: 10.1097/01.NPR.0000000000000258 (opens in new tab) Full text (opens in new tab) Esketamine Electroconvulsive therapy Transcranial magnetic stimulation Treatment-resistant depression trd +5

Exploring the regulatory framework of psychedelics in the US & Europe.

Asian Journal of Psychiatry December 1, 2024 Hitesh Kumar Behera, Ramesh Joga, Sravani Yerram et al.

Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory...

Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta‐analyses of randomized controlled trials

Psychiatry and Clinical Neurosciences Reports December 1, 2024 Itsuki Terao, Wakako Kodama

Abstract The individual efficacy and safety of intravenous racemic (IV) ketamine, psilocybin, and theta burst stimulation (TBS) for major depressive disorder have been demonstrated through meta‐analyses of randomized controlled trials (RCTs), but the comparative usefulness of these novel treatments has not yet been fully examined. We systematically searched the CENTRAL, Medline, CINHAL, and...